ClinicalTrials.gg
Not yet recruitingNCT06986239PCV-LITEUpdated May 22, 2025

Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant

A Phase 1 interventional study of PCV-LITE and PCV-LITE+LVA in Vaccine Reaction, sponsored by LiteVax BV. Not yet recruiting. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by LiteVax BV · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Streptococcus pneumoniae is a common bacteria and major cause of serious infections like bloodstream infections, pneumonia, and meningitis. These infections are most common in children under 2 years old and adults over 65 years of age and dangerous for all age groups. Current vaccines, which contain parts of the bacteria, have significantly reduced the incidence of invasive pneumococcal disease (IPD). To broaden protection more serotypes are added to the vaccines over the years, which results in lower immune responses to the serotype-specific polysaccharides while a stronger vaccine is desired for older people and people with a weakened immune system. In addition, these complex vaccines are hardly affordable for the growing group of older adults in low- and middle-income countries (LMICs). To address these challenges, a new potent adjuvant called 'LiteVax Adjuvant' was developed. It has been shown to improve the efficacy of vaccines, even at low doses of antigen. A lower antigen dose reduces the costs of vaccines and promotes accessibility in LMICs. By testing a standard and a low dose of a commercial pneumococcal conjugate vaccine combined with LiteVax Adjuvant in healthy volunteers, we aim to determine whether the adjuvant enhances the immune response and if a lower vaccine dose is effective. At the same time, the safety of the vaccines is being investigated.

Read the detailed description

The objectives are to evaluate the safety and the immunogenicity of a single intramuscular (IM) injection of a standard dose of PCV20 and a low dose of PCV20 (1/5th) with or without 1 mg of LVA immunoadjuvant.

This study is a randomized, Phase 1, single-center, observer-blind, active-controlled 4-arm study to evaluate the safety, tolerability, and immunogenicity of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine. PCV-LITE consists of 1/5th-dose of PCV20 plus 1 mg of LVA (Cohort 2) and will be compared with 1/5th-dose of PCV20 without adjuvant (Cohort 1), a full dose of PCV20 plus 1 mg of LVA (Cohort 4) and a full dose of PCV20 without adjuvant (Cohort 3). The PCV20 will be the benchmark and the reference vaccine for the three study vaccines.

Cohort 1: 1/5th-dose of PCV20 (reference vaccine diluted in saline), Cohort 2: 1/5th-dose of PCV20 plus 1 mg LVA (study vaccine; PCV-LITE), Cohort 3: full dose of PCV20 (reference vaccine), and Cohort 4: full dose of PCV20 plus 1 mg LVA (study vaccine). A total of 80 participants are planned to be randomized, 20 per cohort. Dose increase of PCV20 (1/5th-dose to a full dose) occurs in two stages (N=40 in each stage). Two consecutive sentinel groups per dose level of PCV20 (first 4 participants on Day 1 followed by 6 participants on Day 4 after an uneventful 72-hours safety follow-up) are implemented to minimize risk to the participants. Participants will randomly be assigned in each stage. A screening visit, a baseline/vaccination visit and 3 follow-up visits at Day 8, Day 29 and Day 181 will be performed. Sentinels will have an additional follow-up telephone contact at Day 4. The study duration for each participant will be up to 21 days of screening, and 180 ± 15 days of follow-up after vaccination.

Participants will be healthy adults aged between 18 and 50 years (inclusive) who have had no laboratory confirmed S. pneumoniae infection in the 36 months prior to study vaccination and have not received an S. pneumoniae vaccination in the 36 months prior to study vaccination.

Interventions: All participants will receive one IM vaccination with the reference or study vaccine. The study vaccine will be prepared by an unblinded pharmacist and administered by an unblinded vaccinator while the participant and other site staff remain blinded (observer-blind). Solicited local and systemic AEs will be recorded in an electronic diary (eDiary) for 14 days after vaccination. The study team will closely monitor the eDiary during the 14-day follow-up period. At Day 15, the Investigator will review the data in the eDiary to determine whether an additional visit is required. If so, the participant should visit the site within 3 days. Unsolicited AEs will be monitored for 28 days after vaccination. SAEs, pIMDs and AESIs will be assessed for 180 days after vaccination. Blood samples (± 12 mL) will be collected from all participants at screening for eligibility evaluation and to examine haematology and biochemistry to check health status. Blood samples will be collected also at the other visits (maximal 20 mL/Visit, 4 visits). In order to evaluate whether the vaccines induce antibodies in the mucosa, mucosal nose swab samples of Mucosal Lining Fluid (MLF) will be collected from all participants at Visit 1/Day 1 and Visit 3/Day 29. The samples will be processed by a local lab (labelled, listed, and frozen) and analyzed by an external laboratory following qualified standard procedures.

02

Conditions studied

  • Vaccine Reaction

Keywords

  • Vaccine adjuvant
  • LiteVax Adjuvant
  • Pneumococcal polysaccharide conjugate vaccine
03

In context

Lead sponsor

LiteVax BV is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Written signed obtained before any study-related activities.
  • Aged 18 to 50 years inclusive, at the time of signing the ICF.
  • Participants who are considered to be in good general health as determined by medical evaluation including medical history, physical examination (PE) and laboratory tests within 21 days prior to enrolment.
  • Participants with a within the range 18.5 to 35 kg/m2 inclusive at screening.
  • Women who are not pregnant or breastfeeding, and one of the following conditions applies:

    • Women of non- (WONCBP) OR
    • WOCBP and using a highly effective method (with a failure rate of less than 1 % per year). Appendices from at least 1 month prior to study vaccination and for 3 months post-vaccination. The investigator should evaluate the potential for contraceptive method failure (e.g. noncompliance, recently initiated) in relationship to study vaccination. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant. The participant should commit to abstinence for at least 1 month prior to study vaccination and for 3 months post-vaccination. If the participant will not maintain abstinence and changes her status, the participant must first commit to another highly effective method of contraception, which should be discussed with the investigator prior to terminating sexual abstinence as contraceptive method.
  • WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test before vaccination at Day 1. The investigator is responsible for review of medical history and menstrual history to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Participants who are willing and able to comply with the study procedures and are in the view of the investigator capable of completing the study.

Exclusion Criteria: Medical Conditions

  • History of laboratory confirmed pneumococcal infection in the past 36 months prior to the day of study vaccination.
  • Positive (in the past, suspected or ongoing) for surface antigen (HBsAg), virus (HCV) antibody, and (HIV) antibody.
  • Past or current history of immune-mediated and/or diseases as indicated by the investigator, e.g. diabetes mellitus type I and thyroid disease.
  • Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator.
  • Clinical conditions representing a for IM administration, as judged by the investigator, e.g. history of bleeding disorder (e.g. factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with IM administration or blood draws.
  • History of confirmed , allergy and/or anaphylaxis to diphtheria toxoid or to squalene-based adjuvants, or other components of the study vaccine (aluminum phosphate, succinic acid, Polysorbate 80).
  • Current history of uncontrolled medical illness (unstable for the past 3 months) as judged by investigator, e.g. hypertension, diabetes mellitus type 2.
  • Past or current history of any neurological disorder, e.g. Guillain-Barré syndrome and seizure disorder other than: 1) childhood febrile seizures, or 2) seizures that have not required treatment within the last 3 years.
  • History of asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen.
  • Active or malignancy within the past 5 years, except basocellular carcinoma (single lesion) that has been fully removed.
  • Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years or that is expected to require the use of oral or intravenous .
  • History of hereditary angioedema, acquired angioedema or idiopathic forms of angioedema.
  • History of idiopathic urticaria within the past year.
  • Current or recent (\< 2 years ago) heavy smoking (> 20 cigarettes per day) or heavy vaping (> 2 mL e-liquid daily, which correspond with 20 cigarettes; reference ). If candidate stopped smoking or vaping > 2 years ago, the investigator would make an individual judgement based on the total packs or use per year and the candidate's overall health status. Drug - or alcohol abuse/addiction (including alcohol dependence), or psychiatric condition (e.g., past or present psychoses; disorder requiring lithium; or within 5 years prior to administration of study vaccine, a history of suicide plan or attempt), which in the investigator's opinion could compromise the participant's safety and/or compliance with the protocol.
  • A rash, dermatological condition or tattoos that would, in the opinion of the investigator, interfere with injection local reaction rating.

Exclusion Criteria: Prior/Concomitant Therapy

  • Prior receipt of an or licensed pneumococcal vaccine in the 36 months before administration of study vaccine or planning to receive a pneumococcal vaccination during the study period.
  • Prior receipt of a in the 28 days prior to administration of study vaccine or within 14 days for subunit or inactivated vaccines other than pneumococcal vaccination.
  • Planning to receive a vaccine during the first 28 days following the administration of study vaccine.
  • Currently participating in another clinical study or planning to participate in another study during the study period, or administration of any investigational drug, vaccine or medical device in the 4 weeks prior to study vaccination.
  • Prior receipt of blood, blood-derived products or immunoglobulins in the 6 months prior to administration of study vaccine or planning to receipt such product during the study period.
  • Chronic administration (defined as 14 consecutive days in total) of or other immune-modifying drugs during the period starting 90 days prior to vaccination or planned administration during the study (excluding topical, inhaled and intranasal preparations and intra-articular injections). For corticosteroids, this is prednisone >= 20 mg/day, or equivalent.
  • Current intake of more than 1 anticoagulant medication (coumarin derivatives, low molecular weight heparin, DOAC) or 1 anticoagulant medication in combination with anti-aggregation medication.
  • Current anti-tuberculosis prophylaxis or therapy.
  • Elective surgery planned in the first 14 days following study vaccination.

Exclusion Criteria:Others

  • WOCBP who are pregnant, breast-feeding or planning to become pregnant during the study.
  • Participants with history of any medical conditions that, in opinion of the investigator, might interfere with the results of the study or pose additional risk to the participants due to participation in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Fractional dose of PCV20

    A single intramuscular injection of 0.5 mL comprising 1/5th dose of Prevenar20 without LiteVax Adjuvant (LVA)

    Biological: PCV-LITE

  • Experimental
    Fractional dose of PCV20 plus LVA

    A single intramuscular injection of 0.5 mL comprising 1/5th dose of Prevenar20 with 1 mg of LiteVax Adjuvant (LVA)

    Biological: PCV-LITE+LVA

  • Active comparator
    Standard dose of PCV20 without LVA

    A single intramuscular injection of 0.5 mL comprising a full dose of Prevenar20 without LiteVax Adjuvant

    Biological: PCV20

  • Experimental
    Standard dose of PCV20 plus 1 mg LiteVax Adjuvant

    A single intramuscular injection of 0.5 mL comprising a full dose of Prevenar20 with LiteVax Adjuvant

    Biological: PCV20+LVA

Interventions

  • BiologicalPCV-LITE

    Fractional dose of pneumococcal polysaccharide conjugate vaccine without LiteVax Adjuvant (LVA)

  • BiologicalPCV-LITE+LVA

    Fractional dose of pneumococcal polysaccharide conjugate vaccine with 1 mg of LiteVax Adjuvant (LVA)

  • BiologicalPCV20

    Standard (full) dose of pneumococcal polysaccharide conjugate vaccine without LiteVax Adjuvant (LVA)

  • BiologicalPCV20+LVA

    Drug page: Pneumococcal 20-Valent Conjugate Vaccine

    Standard (full) dose of pneumococcal polysaccharide conjugate vaccine with LiteVax Adjuvant (LVA)

06

What researchers measure

Primary outcomes

  1. Solicited and non-solicited local and systemic adverse events after a single administration of Prevenar 20 with or without LiteVax adjuvant

    To evaluate the safety and tolerability of a single administration of 1/5th-dose of Prevenar 20 + 1 mg LVA (PCV-LITE), 1/5th-dose of Prevenar 20 without LVA, and a full-dose of Prevenar 20 + 1 mg LVA in comparison to a full-dose of Prevenar 20 without LVA, in healthy participants (18-50 years) * Occurrence of solicited local and systemic adverse events (AEs) for 14 days, unsolicited AEs for 28 days, and serious adverse events (SAEs), potential immune-mediated diseases (pIMDs), and adverse events of special interest (AESIs) for 180 days after vaccination. * Occurrence of clinically abnormal haematology and serum biochemistry laboratory values 1 day, 7 days, and 28 days, after vaccination versus baseline (Day 0, pre-vaccination).

    Time frame: Solicited AEs 14 days, non-solicited AEs 28 days and SAEs/pIMD/AESIs 180 days post-vaccination

Secondary outcomes

  1. Humoral immune responses to a single administration of Prevenar 20 with or without LiteVax Adjuvant by multiplex immune assay (MIA)

    Humoral immune responses to low and full dose of Prevenar 20 with or without LiteVax Adjuvant (LVA) will be determined by a validated multiplex immune assay (MIA) in individual serum samples and expressed as arbitrary units. Geometric mean titers (GMTs), geometric mean concentrations (GMCs), standard deviation (SD), and 95% confidence intervals (95% CI) against the 20 vaccine serotypes will be calculated per cohort.

    Time frame: Pre-vaccination (Day 0) and 28 and 180 days post-vaccination

  2. Humoral immune response to a single administration of Prevenar 20 with or without LiteVax Adjuvant measured by opsonophagocytic activity assay (OPA)

    Humoral immune response to low and full dose of Prevenar 20 with or without LiteVax Adjuvant will be determined by a validated opsonophagocytic activity assay (OPA) in individual serum samples and expressed as arbitrary units. Geometric mean titers (GMTs), geometric mean concentrations (GMCs), standard deviations (SDs), and 95% confidence intervals (95% CIs) against the 20 vaccine serotypes or a selection thereof) will be calculated per cohort

    Time frame: Pre-vaccination (Day 0), 28 days and optionally 180 days post-vaccination

Other outcomes

  1. Functional serum antibody responses

    Functional serum antibody responses to (a selection of) the 20 serotypes of PCV20 will be determined by validated .

    Time frame: Pre-vaccination (Day 0), and 28 and optionally 180 days post-vaccination and pre-vaccination

  2. Mucosal antibody response

    Mucosal (IgG and/or IgA) antibody titers in nasal swabs to (a selection of) the 20 serotypes of PCV20 will be determined by a validated multiplex immune assay (MIA) and expressed as arbitrary units.

    Time frame: Pre-vaccination (Day 0), and 28 days and optionally 180 days post-vaccination

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • van Beek LF, van der Gaast-de Jongh C, Platenburg PP, Hilgers L, de Jonge MI. Improving the immunogenicity of the pneumococcal conjugate vaccine using a synthetic carbohydrate fatty acid monosulphate squalane-in-water adjuvant. Vaccine. 2025 Apr 2;51:126893. doi: 10.1016/j.vaccine.2025.126893. Epub 2025 Feb 20. PubMed 39983540 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Apr 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2025
First posted
May 22, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Apr 1, 2026
CompletionEst.
Jul 1, 2026
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06986239
Lead sponsor
LiteVax BV
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
May 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion